Piper Sandler analyst Jason Bednar raised the firm’s price target on Masimo (MASI) to $210 from $180 and keeps an Overweight rating on the shares. Noting the stock is its top idea for next year, the firm highlights that Masimo participates in one of the better duopolies across MedTech and that it believes the company should see a large reset higher during 2025 in both operating margin and EPS following the impending consumer divestiture, which should support a premium valuation for multiple years until that margin upside is realized.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MASI:
- Masimo Refocuses on Core Healthcare Operations
- Masimo Appoints Michelle Brennan as Interim CEO
- Five Below downgraded, Snowflake upgraded: Wall Street’s top analyst calls
- Masimo price target raised to $180 from $165 at Piper Sandler
- Masimo price target raised to $178 from $170 at BTIG
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
